Methods used to treat cancer
The invention encompasses methods used in the sensitization and treatment of cancer based upon the expression of SGEF.
1. A method of sensitizing a patient with glioblastoma to a radiation therapy and/or chemotherapy, the method comprising the steps of:
administering to the patient with glioblastoma an src-homology 3 domain containing guanine nucleotide exchange factor (SGEF) inhibitor, wherein the SGEF inhibitor sensitizes the glioblastoma to the radiation therapy and/or chemotherapy, and wherein the SGEF inhibitor is a small hairpin RNA targeting the nucleic acid encoding for SGEF.
2. The method of claim 1 , wherein the glioblastoma is invasive.
3. The method of claim 2 , wherein the SGEF inhibitor converts the invasive glioblastoma to a non-migratory phenotype.
4. The method of claim 1 , and further comprising administering a therapeutically effective amount of the radiation therapy and/or chemotherapy to the patient with glioblastoma.
5. The method of claim 4 , wherein the radiation therapy and/or chemotherapy comprises the administration of one or more compounds selected from the group consisting of TROY inhibitors, Pyk2 inhibitors, Rac1 inhibitors, Dock180 inhibitors, Dock7 inhibitors, TWEAK inhibitors, Fn14 inhibitors, BAD inhibitors, and PI3k inhibitors, TRAIL, camptothecin, temozolomide and bevacizumab.
6. A method of treating a patient with invasive glioblastoma, the method comprising the steps of:
a. sensitizing the patient with invasive glioblastoma by reducing an expression level of Src-homology 3 domain containing guanine nucleotide exchange factor (SGEF) using an SGEF inhibitor, wherein the SGEF inhibitor is a small hairpin RNA targeting the nucleic acid encoding for SGEF; and
b. administering a therapeutically effective amount of a radiation therapy and/or chemotherapy to the patient with invasive glioblastoma.
7. The method of claim 6 , wherein the radiation therapy and/or chemotherapy comprises the administration of one or more compounds selected from the group consisting of TROY inhibitors, Pyk2 inhibitors, Rac1 inhibitors, Dock180 inhibitors, Dock7 inhibitors, TWEAK inhibitors, Fn14 inhibitors, BAD inhibitors, and PI3k inhibitors, TRAIL, camptothecin, temozolomide and bevacizumab.
8. The method of claim 6 , wherein the SGEF inhibitor converts the invasive glioblastoma to a non-migratory phenotype.
9. The method of claim 6 , wherein the chemotherapy comprises administering a therapeutically effective amount of temozolomide.
10. The method of claim 6 , wherein the radiation therapy comprises the administration of a therapeutically effective amount of radiation.
11. A method of treating a patient with glioblastoma, the method comprising the steps of:
a. sensitizing the patient with glioblastoma by reducing an expression level of Src-homology 3 domain containing guanine nucleotide exchange factor (SGEF) by administering to the patient a small hairpin RNA targeting SGEF; and
b. administering a therapeutically effective amount of a radiation therapy and/or chemotherapy to the patient with glioblastoma.
12. The method of claim 11 , wherein the radiation therapy and/or chemotherapy comprises the administration of one or more compounds selected from the group consisting of TROY inhibitors, Pyk2 inhibitors, Rac1 inhibitors, Dock180 inhibitors, Dock7 inhibitors, TWEAK inhibitors, Fn14 inhibitors, BAD inhibitors, and PI3k inhibitors, TRAIL, camptothecin, temozolomide and bevacizumab.
13. The method of claim 11 , wherein the radiation therapy comprises the administration of a therapeutically effective amount of radiation.